A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Single-dose, Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IW-1701 in Patients With Achalasia
Phase of Trial: Phase II
Latest Information Update: 01 Jun 2017
At a glance
- Drugs IW 1701 (Primary)
- Indications Achalasia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Ironwood Pharmaceuticals
- 08 May 2017 Data from this study are expected in the second half of 2017, according to an Ironwoord Pharmaceuticals media release.
- 21 Feb 2017 According to an Ironwood Pharmaceuticals media release, status changed from not yet recruiting to recruiting.
- 03 Nov 2016 According to an Ironwood Pharmaceuticals media release, data from this trial are expected in 2017.